Phage therapy-constraints and possibilities

Upsala Journal of Medical Sciences

Volumn 119, Issue 2, 2014, Pages 192-198

  Nilsson, Anders S ^a  

^a STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

Antibiotic resistance; Bacteriophage; Phage; Phage therapy

Indexed keywords

ANIMAL; BACTERIAL INFECTIONS; BACTERIOPHAGE; HUMAN;

ANIMALS; BACTERIAL INFECTIONS; BACTERIOPHAGES; HUMANS;

EID: 84900867912     PISSN: 03009734     EISSN: None     Source Type: Journal    
DOI: 10.3109/03009734.2014.902878     Document Type: Review

References (43)

1. Henry M, Lavigne R, Debarbieux L. Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections. Antimicrob Agents Chemother. 2013; 57:5961-8.
2. Tsonos J, Oosterik LH, Tuntufye HN, Klumpp J, Butaye P, De Greve H, et al. A cocktail of in vitro efficient phages is not a guarantee for in vivo therapeutic results against avian colibacillosis. Vet Microbiol. 2013;Epub ahead of print.
3. Abedon ST, Thomas-Abedon C. Phage therapy pharmacology. Curr Pharm Biotechnol. 2010;11:28-47.
4. Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogkhia L, Kuhl S, et al. Phage therapy in clinical practice: treatment of human infections. Curr Pharm Biotechnol. 2010;11:69-86.
5. Lu TK, Collins JJ. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc Natl Acad Sci USA. 2009;106:4629-34.
6. Gilmer DB, Schmitz JE, Euler CW, Fischetti VA. Novel bacteriophage lysin with broad lytic activity protects against mixed infection by Streptococcus pyogenes and methicillinresistant Staphylococcus aureus. Antimicrob Agents Chemother. 2013;57:2743-50.
7. Pastagia M, Schuch R, Fischetti VA, Huang DB. Lysins: the arrival of pathogen-directed anti-infectives. J Med Microbiol. 2013;62:1506-16.
8. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacteriophage. 2011;1:66-85.
9. Loc-Carillo C, Abedon ST. Pros and cons of phage therapy. Bacteriophage. 2011;1:111-14.
10. Knoll BM, Mylonakis E. Antibacterial bio-agents based on principles of bacteriophage biology: an overview. Clin Infect Dis. 2014;58:528-34.
11. Gill J, Hyman P. Phage choice, isolation, and preparation for phage therapy. Curr Pharm Biotechnol. 2010;11:2-14.
12. Denou E, Bruttin A, Barretto C, Ngom-Bru C, Brussow H, Zuber S. T4 phages against Escherichia coli diarrhea: potential and problems. Virology. 2009;388:21-30.
13. Brüssow H. Phage therapy: quo vadis? Clin Infect Dis. 2014; 58:535-6.
14. Dennehy JJ. What can phages tell us about host-pathogen coevolution? Int J Evol Biol. 2012;2012:396165.
15. Levin BR, Bull JJ. Population and evolutionary dynamics of phage therapy. Nat Rev Microbiol. 2004;2:166-73.
16. Gasiunas G, Sinkunas T, Siksnys V. Molecular mechanisms of CRISPR-mediated microbial immunity. Cell Mol Life Sci. 2014;71:449-65.
17. Szczepankowska A. Role of CRISPR/cas system in the development of bacteriophage resistance. Adv Virus Res. 2012;82: 289-338.
18. Molineux IJ. Host-parasite interactions: recent developments in the genetics of abortive phage infections. New Biol. 1991;3: 230-6.
19. Fineran PC, Blower TR, Foulds IJ, Humphreys DP, Lilley KS, Salmond GP. The phage abortive infection system, ToxIN, functions as a protein-RNA toxin-antitoxin pair. Proc Natl Acad Sci USA. 2009;106:894-9.
20. Jiang W, Maniv I, Arain F, Wang Y, Levin BR, Marraffini LA. Dealing with the evolutionary downside of CRISPR immunity: bacteria and beneficial plasmids. PLoS Genet. 2013;9: e1003844.
21. Seed KD, Lazinski DW, Calderwood SB, Camilli A. A bacteriophage encodes its own CRISPR/Cas adaptive response to evade host innate immunity. Nature. 2013;494: 489-91.
22. Weld RJ, Butts C, Heinemann JA. Models of phage growth and their applicability to phage therapy. J Theor Biol. 2004; 227:1-11.
23. Bancroft FC, Freifelder D. Molecular weights of coliphages and coliphage DNA. I. Measurement of the molecular weight of bacteriophage T7 by high-speed equilibrium centrifugation. J Mol Biol. 1970;54:537-46.
24. Molineux IJ. The T7 group. In Calendar R, editor. The bacteriophages. New York: Oxford University Press; 2006. p 277-301.
25. Dubin SB, Benedek GB, Bancroft FC, Freifelder D. Molecular weights of coliphages and coliphage DNA. II. Measurement of diffusion coefficients using optical mixing spectroscopy, and measurement of sedimentation coefficients. J Mol Biol. 1970;54:547-56.
26. Geier MR, Trigg ME, Merril CR. Fate of bacteriophage lambda in non-immune germ-free mice. Nature. 1973;246: 221-3.
27. Payne RJH, Jansen VAA. Understanding bacteriophage therapy as a density-dependent kinetic process. J Theor Biol. 2001;208:37-48.
28. Merril CR, Scholl D, Adhya S. Phage therapy. In Calendar R, editor. The bacteriophages. New York: Oxford University Press; 2006. p 725-41.
29. Saussereau E, Debarbieux L. Bacteriophages in the experimental treatment of Pseudomonas aeruginosa infections in mice. Adv Virus Res. 2012;83:123-41.
30. Chan BK, Abedon ST. Phage therapy pharmacology: phage cocktails. Adv Appl Microbiol. 2012;78:1-23.
31. Wei Y, Kirby A, Levin BR. The population and evolutionary dynamics of Vibrio cholerae and its bacteriophage: conditions for maintaining phage-limited communities. Am Nat. 2011; 178:715-25.
32. Reyes A, Semenkovich NP, Whiteson K, Rohwer F, Gordon JI. Going viral: next-generation sequencing applied to phage populations in the human gut. Nat Rev Microbiol. 2012;10:607-17.
33. Sarker SA, McCallin S, Barretto C, Berger B, Pittet AC, Sultana S, et al. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. Virology. 2012; 434:222-32.
34. McCallin S, Alam Sarker S, Barretto C, Sultana S, Berger B, Huq S, et al. Safety analysis of a Russian phage cocktail: from metagenomic analysis to oral application in healthy human subjects. Virology. 2013;443:187-96.
35. Wright A, Hawkins CH, Anggard EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol. 2009;34:349-57.
36. Merabishvili M, Pirnay JP, Verbeken G, Chanishvili N, Tediashvili M, Lashkhi N, et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS ONE. 2009; 4:e4944.
37. Sokoloff AV, Bock I, Zhang G, Sebestyen MG, Wolff JA. The interactions of peptides with the innate immune system studied with use of T7 phage peptide display. Mol Ther. 2000;2: 131-9.
38. Biswas B, Adhya S, Washart P, Paul B, Trostel AN, Powell B, et al. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun. 2002;70:204-10.
39. Skurnik M, Pajunen M, Kiljunen S. Biotechnological challenges of phage therapy. Biotechnol Lett. 2007;29:995-1003.
40. McGannon CM, Fuller CA, Weiss AA. Different classes of antibiotics differentially influence shiga toxin production. Antimicrob Agents Chemother. 2010;54:3790-8.
41. Verbeken G, Pirnay JP, Lavigne R, Jennes S, De Vos D, Casteels M, et al. Call for a dedicated European legal framework for bacteriophage therapy. Arch Immunol Ther Exp (Warsz). 2014;62:117-29.
42. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012;11:191-200.
43. Eichler HG, Oye K, Baird LG, Abadie E, Brown J, Drum CL, et al. Adaptive licensing: taking the next step in the evolution of drug approval. Clin Pharmacol Ther. 2012; 91:426-37.